{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:48:29Z","timestamp":1778600909628,"version":"3.51.4"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","award":["00"],"award-info":[{"award-number":["00"]}],"id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The Italian Sarcoma Group performed this retrospective analysis of patients with advanced soft tissue sarcoma, pretreated with \u22651 anthracycline-based treatment, and treated with trabectedin every three weeks. Primary endpoint was to describe real-life use of trabectedin across Italy. Secondary endpoints included objective response rate (ORR) and safety. Overall, 512 patients from 20 Italian centers were evaluated. Leiomyosarcoma (37.7%)\/liposarcoma (30.3%) were the most prevalent histological types (abbreviated as L-sarcoma). Patients received a median of four trabectedin cycles (range: 1\u201340), mostly as a second-line treatment (~60% of patients). The ORR was 13.7% superior (p &lt; 0.0001) in patients with L-sarcoma compared with patients with non-L-sarcoma (16.6% vs. 9.0%). Median progression-free survival (PFS) was 5.1 months, whereas median overall survival (OS) was 21.6 months. Significantly better PFS and OS were observed in patients with L-sarcoma, those with objective responses and\/or disease stabilization, treated in an early line and treated with reduced dose. Bone marrow toxicity (61.4%) and transaminase increases (21.9%) were the most common grade 3\/4 adverse events. The results of this real-life study suggest that trabectedin is an active treatment, which is mostly given as a second-line treatment to patients with a good performance status and high-grade, metastatic L-sarcoma (clinical trial information: NCT02793050).<\/jats:p>","DOI":"10.3390\/cancers13051053","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T10:36:37Z","timestamp":1614681397000},"page":"1053","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-6705","authenticated-orcid":false,"given":"Emanuela","family":"Palmerini","sequence":"first","affiliation":[{"name":"Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 1 Via Pupilli, 40136 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133 Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-569X","authenticated-orcid":false,"given":"Giovanni","family":"Grignani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, Candiolo, 10060 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-0308","authenticated-orcid":false,"given":"Angela","family":"Buonadonna","sequence":"additional","affiliation":[{"name":"Centro di Riferimento Oncologico di Aviano (CRO Aviano), IRCCS, Via Franco Gallini 2, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Romanini","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-8838","authenticated-orcid":false,"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Piazza Marina 61, 90133 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Ferraresi","sequence":"additional","affiliation":[{"name":"IRCCS Regina Elena National Cancer Institute-Division of Medical Oncology 1-Via Elio Chianesi 53, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Comandone","sequence":"additional","affiliation":[{"name":"SC Oncologia ASL Citt\u00e0 di Torino, Ospedale San Giovanni Bosco Torino, Piazza del Donatore di Sangu, 3, 10154 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pizzolorusso","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, Via Mariano Semmola 53, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-5226","authenticated-orcid":false,"given":"Antonella","family":"Brunello","sequence":"additional","affiliation":[{"name":"Oncology 1 Unit, Istituto Oncologico Veneto IOV\u2013IRCCS, Via Gattamelata 64, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Gelsomino","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, University Hospital of Modena, Via del Pozzo 71, 41124 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5684-5254","authenticated-orcid":false,"given":"Tommaso De","family":"Pas","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology Sarcomas, Thymomas and Rare Tumors, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20121 Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-4167","authenticated-orcid":false,"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, Via Piero Maroncelli 40, 47014 Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[{"name":"Mesothelioma and Rare Cancer Unit, Azienda Ospedaliera SS. Antonio e Biagio General Hospital, Via Venezia, 16, 15121 Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Zanelli","sequence":"additional","affiliation":[{"name":"Dipartimento Oncologico e Tecnologie Avanzate, Arcispedale Santa Maria Nuova IRCCS Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Abbondanza","family":"Pantaleo","sequence":"additional","affiliation":[{"name":"Division of Oncology, IRCSS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Milesi","sequence":"additional","affiliation":[{"name":"Depatement of Oncology, ASST. Papa Giovanni XXIII Hospital, Piazza OMS, 1, 24127 Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libero","family":"Ciuffreda","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda Ospedaliero Universitaria San Giovanni Battista, Molinette, Via Santena 5, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Dipartimento di Specialit\u00e0 Medico-Chirurgiche, Scienze Radiologiche e Sanit\u00e0 Pubblica, Oncologia Medica, Universit\u00e0 degli Studi di Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Marchesi","sequence":"additional","affiliation":[{"name":"Italian Sarcoma Group Clinical Trial Unit, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Quattrini","sequence":"additional","affiliation":[{"name":"Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 1 Via Pupilli, 40136 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-0155","authenticated-orcid":false,"given":"Alberto","family":"Righi","sequence":"additional","affiliation":[{"name":"Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1\/10, 40136 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-3290","authenticated-orcid":false,"given":"Elisabetta","family":"Setola","sequence":"additional","affiliation":[{"name":"Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1\/10, 40136 Bologna, Italy"},{"name":"Department of Experimental, Diagnostic an Speciality Medicine, Alma Mater Studiorum, University of Bologna, Via Zamboni, 33, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-6000","authenticated-orcid":false,"given":"Elisa","family":"Carretta","sequence":"additional","affiliation":[{"name":"Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 1 Via Pupilli, 40136 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-4101","authenticated-orcid":false,"given":"Piero","family":"Picci","sequence":"additional","affiliation":[{"name":"Laboratory of Oncologic Research, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1\/10, 40136 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 1 Via Pupilli, 40136 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1002\/cncr.27555","article-title":"Incidence of soft tissue sarcoma and beyond","volume":"118","author":"Mastrangelo","year":"2012","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"iv268","DOI":"10.1093\/annonc\/mdy321","article-title":"Corrections to \u201cSoft tissue and visceral sarcomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up\u201d","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/annonc\/mds659","article-title":"Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: Results of a worldwide expanded access program study","volume":"24","author":"Samuels","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejca.2013.11.011","article-title":"International expert opinion on patient-tailored management of soft tissue sarcomas","volume":"50","author":"Blay","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fon.13.207","article-title":"Trabectedin mechanism of action: What\u2019s new?","volume":"9","year":"2013","journal-title":"Futur. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A Review of Trabectedin (ET-743): A Unique Mechanism of Action","volume":"9","author":"Galmarini","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/cncr.32117","article-title":"Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"key":"ref_12","first-page":"33","article-title":"Efficacy of trabectedin in patients with some rare advanced soft tissue sarcoma subtypes other than liposarcoma and leiomyosarcoma","volume":"5","author":"Reichardt","year":"2015","journal-title":"J. Med. Drug Rev."},{"key":"ref_13","first-page":"5785","article-title":"Efficacy of trabectedin in advanced soft tissue sarcoma: Beyond lipo- and leiomyosarcoma","volume":"9","author":"Marrari","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(15)70098-7","article-title":"Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: A randomised, open-label, phase 2 study","volume":"16","author":"Kawai","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Blay, J.-Y., Italiano, A., Ray-Coquard, I., Le Cesne, A., Duffaud, F., Rios, M., Collard, O., Bertucci, F., Bompas, E., and Isambert, N. (2013). Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: An analysis of 181 patients of the French ATU compassionate use program. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-64"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejca.2015.01.006","article-title":"Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group","volume":"51","author":"Duffaud","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/CAD.0000000000000560","article-title":"A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma","volume":"28","author":"Buonadonna","year":"2017","journal-title":"Anti-Cancer Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/CAD.0000000000000228","article-title":"Trabectedin in advanced synovial sarcomas","volume":"26","author":"Sanfilippo","year":"2015","journal-title":"Anti-Cancer Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/his.12311","article-title":"Liposarcomas: Diagnostic pitfalls and new insights","volume":"64","author":"Tos","year":"2013","journal-title":"Histol. Histopathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","article-title":"Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens\u2014A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study","volume":"17","author":"Oosterhuis","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/bjc.2013.524","article-title":"Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: A retrospective pooled analysis of five phase II trials","volume":"109","author":"Cesne","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ejca.2015.03.023","article-title":"A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial","volume":"51","author":"Butrynski","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_24","first-page":"1193","article-title":"A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials","volume":"30","author":"Yovine","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000505393","article-title":"Long-Term Response after 94 Cycles of Trabectedin in a Patient with Metastatic Leiomyosarcoma of the Lower Extremity","volume":"13","author":"Cordeiro","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(15)70031-8","article-title":"Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): A randomised phase 2 trial","volume":"16","author":"Blay","year":"2015","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/5\/1053\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:31:27Z","timestamp":1760160687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/5\/1053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["cancers13051053"],"URL":"https:\/\/doi.org\/10.3390\/cancers13051053","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]}}}